TNFRSF21 and ovarian carcinoma: It has been reported that DR6 can serve as a serum vasculature marker in ovarian cancer development.2 And as a vascular biomarker, DR6 expresses highly in gynecological malignancy19 and breast carcinoma.20 DR6 knockout animals showed that DR6 is required for central nervous system-specific angiogenesis.6 These findings were similar to our data for DR6 in melanoma tumor angiogenesis; our model could be therefore further exploited for melanoma therapy strategies and for prognosis via vascular diagnosis.